Because the benefit of TMZ in patients with unmethylated MGMT GBM is controversial and its withholding for this group has been proposed [27, 28], we expanded the study to include three patients with unmethylated MGMT who received weekly EGFR BATs without adjuvant TMZ. The gene discussed is EGFR; the disease is glioblastoma.